Company Overview
Galectin Therapeutics develops therapies targeting galectin proteins, focusing on its lead drug, belapectin, for MASH cirrhosis.
Key Financial Figures
For the year ended December 31, 2025, the company reported a basic and diluted net loss Earnings Per Share (EPS) of $(0.48). The provided financial statements do not report any Revenue.
Additional Financial Insights
The company ended 2025 with $17.7 million in unrestricted cash and cash equivalents. Research and development expenses decreased significantly to $14.3 million from $36.6 million in 2024 due to the NAVIGATE clinical trial’s conclusion.